Cg Oncology Inc. Earnings

Cg Oncology Inc.’s revenue jumped 377.78% since last year same period to $0.04Mn in the Q3 2024. On a quarterly growth basis, Cg Oncology Inc. has generated -61.26% fall in its revenue since last 3-months.

Cg Oncology Inc.’s net profit fell -67.16% since last year same period to $-20.41Mn in the Q3 2024. On a quarterly growth basis, Cg Oncology Inc. has generated -7.95% fall in its net profits since last 3-months.

Cg Oncology Inc.’s net profit margin jumped 65.01% since last year same period to -47453.49% in the Q3 2024. On a quarterly growth basis, Cg Oncology Inc. has generated -178.67% fall in its net profit margins since last 3-months.

Cg Oncology Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.34 - a -8.13% fall from last quarter’s estimates.

Cg Oncology Inc.’s earning per share (EPS) estimates for the current year stand at -0.34.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Cg Oncology Inc.’s return on assets (ROA) stands at -0.16.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Cg Oncology Inc.’s return on equity (ROE) stands at -0.2.